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Abstract
Cocoa flavanols (CF) positively influence physiological processes in ways which suggest that their consumption may improve aspects of cognitive
function. This study investigated the acute cognitive and subjective effects of CF consumption during sustained mental demand. In this randomized,
controlled, double-blinded, balanced, three period crossover trial 30 healthy adults consumed drinks containing 520 mg, 994 mg CF and a matched
control, with a 3-day washout between drinks. Assessments included the state anxiety inventory and repeated 10-min cycles of a Cognitive Demand
Battery comprising of two serial subtraction tasks (Serial Threes and Serial Sevens), a Rapid Visual Information Processing (RVIP) task and a ‘mental
fatigue’ scale, over the course of 1 h. Consumption of both 520 mg and 994 mg CF significantly improved Serial Threes performance. The 994 mg
CF beverage significantly speeded RVIP responses but also resulted in more errors during Serial Sevens. Increases in self-reported ‘mental fatigue’ were
significantly attenuated by the consumption of the 520 mg CF beverage only. This is the first report of acute cognitive improvements following
CF consumption in healthy adults. While the mechanisms underlying the effects are unknown they may be related to known effects of CF on endothelial
function and blood flow.
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Introduction
Flavonoids are a diverse class of natural compounds, ubiqui-
tous in plants. Within the human diet, several subcategories
of ﬂavonoids predominate, including ﬂavanols, ﬂavonols, iso-
ﬂavones, ﬂavones, ﬂavanones, and anthocyanidins. Among
the dietary ﬂavonoids, high levels of ﬂavanols are found in
numerous common food stuﬀs such as grapes, red wine,
apples, both green and black teas, and cocoa and
cocoa-containing products (Gu et al., 2004). They are partic-
ularly abundant in cocoa where the number and arrangement
of ﬂavanols is distinct, containing both the simple monomeric
ﬂavanols (primarily (–)-epicatechin and to a much lesser
extent, (+)-catechin) as well as the structurally related
dimeric and oligomeric ﬂavanols known as procyanidins
(Lazarus et al., 1999).
Over the past decade, there has been increasing interest in
the potential health beneﬁts associated with the consumption
of ﬂavanol-containing foods, some of which are likely to have
ramiﬁcations for cognitive function. Dietary intervention
trials have shown that the consumption of ﬂavanol-containing
cocoa products can reduce platelet aggregation (Holt et al.,
2002) and improve insulin sensitivity (Grassi et al., 2005), and
blood pressure (Taubert et al., 2007).There is also increasing
evidence that consumption of cocoa ﬂavanols (CF) can
improve a host of parameters reﬂecting improved peripheral
and central blood ﬂow (Engler et al., 2004; Heiss et al., 2005,
2007; Schroeter et al., 2006; Flammer et al., 2007). While the
mechanisms underlying these eﬀects remain to be elucidated,
they may be related to increased nitric oxide synthesis within
blood vessels (Fisher et al., 2003; Heiss et al., 2003; Balzer et
al., 2008). There is also evidence of subchronic and acute
increases in blood ﬂow following ingestion of cocoa (Balzer
et al., 2008; Davison et al., 2008; Faridi et al., 2008). Of par-
ticular relevance to the current study is the ﬁnding that CF
ingestion is associated with increased cerebral blood ﬂow and
brain activation. Francis et al (2006) examined the eﬀects of
CF administration on brain activation during a cognitive
task. Subjects received 150mg/day CF or a control drink
for 5 days. On day 5 they underwent cognitive testing
and functional magnetic resonance imaging (fMRI).
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Compared with the control, the CF condition was associated
with greater activation of task-relevant brain loci (dorsolat-
eral prefrontal cortex, anterior cingulate and parietal cortex).
As the participants had received CF on the assessment day
(day 5 of the subchronic trial), the possibility of acute eﬀects
on cerebral metabolism could not be precluded. The authors
therefore examined the acute eﬀects of CF on cerebral blood
ﬂow (CBF), measured using arterial spin labelling MRI, in a
pilot study with four volunteers. CF ingestion resulted in
increased CBF which was apparent by the ﬁrst (2 h) time
point and returned to baseline by the ﬁnal 6 h measure.
Despite the increased CBF and cortical activation, there
was no concomitant improvement in task performance in
the ﬁrst part of the Francis study. The study used an execu-
tive/attentional switching task with relatively heavy task
demands. However, prior to the intervention phase, partici-
pants were trained to a high performance criterion (greater
than 95% accuracy) therefore it is possible that performance
was approaching ceiling minimising the possibility of
enhancement through CF ingestion.
More recently Crews et al. (2008) evaluated the cognitive
eﬀects of cocoa. Over-60-year-olds were administered 37 g
dark chocolate (397mg cocoa procyanidins) and a 273-ml
cocoa drink (total 357mg cocoa procyanidins) or matching
placebo products daily for 6weeks. There were no treatment-
related changes in cognitive function, or in numerous physi-
ological or other biomarkers measured during mid-point or
end-point assessments. While these ﬁndings might suggest no
eﬃcacy for CF (procyanidins) in the cognitive arena, the
authors of that study themselves acknowledge that the lack
of eﬀects may be due to either a ﬂavonoid-rich habitual diet
or the fact that these were cognitively high functioning indi-
viduals. Pulse rate was signiﬁcantly elevated at weeks 3 and 6
in the cocoa group suggesting that the treatment was having
some physiological eﬀect over and above diet though the
authors suggest that this may be attributable to the methyl-
xanthines (caﬀeine and theobromine) present in cocoa pro-
ducts. Again the possibility that participants were
approaching ceiling performance, thereby minimising any
CF eﬀects on cognition, cannot be ruled out.
One way of eﬀectively eliminating ceiling eﬀects is to sub-
ject participants to sustained eﬀortful processing which leads
to a progressive performance decline even in healthy young
adults. This approach has proved to be a sensitive means of
capturing the positive cognitive eﬀects of a number of dietary
interventions. The Cognitive Demand Battery (CDB) consists
of repeated cycles of Serial Threes, Serial Sevens, the Bakan
Rapid Visual Information Processing task and self-rated
‘mental fatigue.’ Over six repetitions mental fatigue ratings
are reliably increased while performance declines. A series
of double-blinded, placebo-controlled trials has revealed
that aspects of this decline can be protected to some degree
by administration of caﬀeine-glucose drinks (Kennedy and
Scholey, 2004), by ginseng (Reay et al., 2005, 2006), glucose
(Reay et al., 2006) and by a multivitamin-guarana´ combina-
tion (Kennedy et al., 2008).
While the mechanisms underlying these eﬀects are
unknown, increasing the provision of metabolic substrates
can result in cognition enhancement. Thus inhalation of pure
oxygen (e.g. Moss et al., 1998; Scholey et al., 1999) or imbibing
glucose (e.g. Benton et al., 1994) can enhance cognitive perfor-
mance. It also appears that such eﬀects are more marked
during cognitive processing involving a relatively high level
of mental eﬀort (Kennedy and Scholey, 2000; Scholey et al.,
2001, 2003, 2008). In addition, studies that have shown
improved cognitive performance following the consumption
of plant extracts such as Panax ginseng, Ginkgo biloba which
may be related to their ability to enhance cerebral blood ﬂow,
oxygen utilization or glucose metabolism (Scholey and Kennedy,
2002; Reay et al., 2005, 2006). Given their eﬀects on vascular
function and blood ﬂow, we hypothesized that the consump-
tion of CF should positively modulate performance on men-
tally demanding tasks and ameliorate the increase in mental
fatigue associated with performing such tasks.
The current controlled, randomized, double-blinded,
balanced cross-over study therefore examined the acute cog-
nitive and mood eﬀects of diﬀering levels of CF in a cocoa
drink. The eﬀects of consuming 520mg and 994mg CF on
these parameters were compared to those of a nutrient-
matched, low ﬂavanol control drink.
Materials and methods
Design
This was a double-blinded, placebo-controlled, three period
crossover study. On diﬀerent visits participants underwent
the Cognitive Demand Battery following consumption of a
low CF control drink and drinks containing 520mg and
994mg of CF.
Participants
Thirty healthy non-smoking undergraduate and postgradu-
ate student volunteers (13male) were each paid 80 to par-
ticipate in the study. The cohort had a mean age of
21.9 years (range 18–35, SEM 0.61 years) and mean BMI
of 23.0 ( 0.62 kg/m2). They were informed that they would
be taking part in a psychological study investigating the
eﬀects of cocoa components on mental function. All parti-
cipants reported that they were in good health and free from
illicit drugs and over-the-counter or prescription medication
(with the exception of the contraceptive pill). Participants
abstained from chocolate/cocoa consumption, caﬀeine and
alcohol consumption for a minimum of 12 h prior to
the ﬁrst testing session, and throughout the morning until
the ﬁnal testing session was completed. A diary was pro-
vided to allow participants to record all food and drink
consumption for 24 h prior to the ﬁrst test session of each
study day. It was recommended to participants that they
should avoid food and beverages which are high in ﬂavo-
noid content for 24 h preceding each study day. A list of
such products was provided to the participants (it was
stressed that this was merely a recommendation and honesty
in ﬁlling out the diary was more important). This request for
restricted ﬂavonoid diet was intended to allow acute changes
in plasma ﬂavanol levels to be monitored. The study was
approved by the Northumbria University Division of
Psychology Ethics Committee, and was conducted in accor-
dance with the Declaration of Helsinki.
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Salivary caffeine levels
Saliva samples were obtained using salivettes (Sarstedt,
Leicester, UK). Samples were taken immediately following
baseline assessment in order to conﬁrm compliance to over-
night abstinence, and following the post-treatment assessment
session to conﬁrm uniform caﬀeine absorption across condi-
tions. The saliva samples were immediately frozen at 20C
until thawing for in-house batch analysis using the Emit
system (Syva, Palo Alto, USA). This is an enzyme immunoas-
say intended to measure caﬀeine as a metabolite and is based
on competition for antibody binding sites between caﬀeine
and an enzyme labelled drug.
State-Trait Anxiety Inventory (STAI) state scale
The STAI state scale (Speilberger et al., 1969) was adminis-
tered as a self-completed questionnaire. The scale contains 20
four-point items which record the presence (e.g. ‘I am tense’)
and absence (e.g. ‘I feel at ease’) of anxiety symptoms. These
are combined to provide a sum score between 20 and 80
(a lower score representing lower anxiety). The scale is sensi-
tive to laboratory stressors and certain dietary manipulations
(Kennedy et al., 2005).
Cognitive Demand Battery (CDB)
The Cognitive Demand Battery comprised of two computer-
ized serial subtraction tasks (Serial Threes and Serial Sevens)
the Bakan Rapid Visual Information Processing task (RVIP)
and a paper-and-pencil mental fatigue scale implemented as
follows:
(1) Serial Threes subtraction task: Participants were required
to count backwards in threes from a given number as
quickly and as accurately as possible using the computer
keyboard number keys to enter each response. A random
starting number between 800 and 999 was presented on
the computer screen, which was cleared by the entry of
the ﬁrst response. The task was scored for number of
correct responses and number of errors. In the case of
incorrect responses, subsequent responses were scored as
positive if they were scored as correct in relation to the
new number for details see Scholey et al. (2001). The
duration of this task was 2min.
(2) Serial Sevens subtraction task: This was identical to the
Serial Threes task with the exception that it involved
serial subtraction of sevens. Again the duration was 2min.
(3) RVIP task: The participant was required to monitor a con-
tinuous series of digits for targets of three consecutive odd
or three consecutive even digits. The digits were presented
at the rate of 100 per minute and the participant responded
to the detection of a target string by pressing the ‘space bar’
as quickly as possible. The task was continuous, with eight
correct target strings being presented in each minute. The
task was scored for percentage of target strings correctly
detected, average reaction time for correct detections, and
number of false alarms. The task lasted for 5min.
(4) ‘Mental fatigue’ visual analogue scale: Participants rated
their current subjective mental fatigue state by making
a mark on a 100mm Visual Analogue Scale (VAS) with
the end points labelled ‘not at all’(left hand end) and ‘very
much so’(right hand end). One minute was allowed to
complete the VAS.
The total duration of each cycle of the CDB (Serial Threes,
Serial Sevens, RVIP, ‘mental fatigue’ VAS) was 10min.
Flavanol-containing test drinks
On each day of testing participants consumed one of three
dairy-based cocoa drinks containing a total of either: 1) 46mg
CF (‘control’); 2) 520mg cocoa ﬂavanols (’520CF’), or 3)
994mg cocoa ﬂavanols (’994CF’). The lower level coincides
with the CF drink which produced increased brain–blood
ﬂow at 2 h (Francis et al., 2006). Total cocoa ﬂavanol content
is deﬁned here as the sum of all monomeric ﬂavanols and
their structurally related dimeric and oligomeric procyanidins
up to decamer. The total cocoa ﬂavanol content was deter-
mined by Mars Inc according to published methodology
(Robbins et al., 2008).
Test products were manufactured and supplied by Mars
(Leicestershire, UK) as a dry cocoa blend in individually
wrapped sachets, coded with a three-digit random number.
These were stored in a cool, dry environment prior to drink
preparation. The sachets contained either 23mg cocoa ﬂava-
nols/sachet (‘low ﬂavanol’ cocoa drink mix) or 497mg CF/
sachet (‘high ﬂavanol’ cocoa drink mix). The high ﬂavanol
cocoa drink mixes were prepared using a Cocoapro pro-
cessed cocoa powder, To ensure that the macronutrients,
micronutrients, and alkaloids (caﬀeine and theobromine)
were matched in all conditions of the study, two sachets of
the beverage mixes were combined to produce the control
drink (2 ‘low ﬂavanol’ sachets, 46mg CF); the 520mg CF
drink (1 ‘low ﬂavanol,’ 1 ‘high ﬂavanol’ sachet), or the
994mg CF drink (2 ‘high ﬂavanol’ sachets). Details of the
nutritional information for the preparations can be found in
Table 1. On the day of testing, coded drinks were prepared by
mixing the two sachets with 200ml hot water by a disinter-
ested third party staﬀ member who was not involved in the
study and who played no further part in the experiment.
The study participants were asked to consume the drink
within 5min. The general composition of the drinks was as
follows: non-fat dry milk powder (59.0%); cocoa powder
(33%), ﬁbre (5.6%); emulsiﬁer (0.8%); cellulose gel
(0.55%); xanthan gum (0.55%); artiﬁcial and natural vanilla
(0.1%); and sucralose (0.1%).
Procedure
Prior to participation in the study, volunteers signed an
informed consent form and completed a medical health ques-
tionnaire. Each participant was required to attend a total
of four study days (one practice visit and three study visits)
that were conducted not less than three days apart to ensure
suﬃcient wash out between conditions. They were asked
to consume the same light breakfast on study days (this
was checked using the food diaries). Testing took place in a
suite of dedicated university laboratories with participants
visually isolated from each other. On arrival at their ﬁrst
Scholey et al 3
XML Template (2009) [17.9.2009–6:11pm] [1–10]
K:/JOP/JOP 106923.3d (JOP) [INVALID Stage]
session on the ﬁrst day, participants were randomly allocated
to one of six treatment orders of the Latin square design
that counterbalanced the order of treatments across the three
study days of the study. Prior to these a practice visit
involved completion of the test battery six times. This was
undertaken in order to control for practice eﬀects and to
allow familiarization with the test battery and procedure on
subsequent visits. The practice day data were not included in
any analyses.
The structure of each of the three active study days is
summarized in Figure 1. Following arrival at the laboratory
and a short assimilation period, participants provided a 2ml
venous blood sample for determination of serum ﬂavonoid
levels, ﬁlled out the state portion of the Spielberger state-
trait anxiety inventory, and completed an initial practice
run through the 10min Cognitive Demand Battery. This con-
sisted of Serial Threes (2min), Serial Sevens (2min), RVIP
(5min), and the ‘mental fatigue’ VAS (1min). The computer-
ized tests were administered on Dell PCs running Windows.
Participants completed a pre-dose 10-min Cognitive Demand
Battery in order to establish that day’s baseline performance.
They then provided a pre-treatment saliva sample using a
salivette for determination of caﬀeine levels (this was taken
at the last opportunity prior to CF consumption to maximise
the detection of caﬀeine from products consumed on
the morning of study days). This was followed immediately
by ingestion of that day’s drink (ﬁve minutes was allowed
for consumption). Starting a ﬁxed 90min following
beverage consumption (during which participants were
allowed to leave the laboratory but were instructed to con-
sume nothing other than water and to avoid any strenuous
exercise), participants underwent the Cognitive Demand
Battery a further six times in succession (i.e. for 60min in
total). They then provided a second, ﬁnal saliva sample.
Study visits were repeated at the same time of day for each
participant, starting at 0815 and 0930, until all treatments had
been completed.
Data treatment and statistics
The primary outcomes were the performance and
fatigue scores during the Cognitive Demand Battery (CDB).
There were eight CDB measures which were analysed as
change-from-baseline scores: number of errors and number
of correct responses from both Serial Subtractions tasks; %
accuracy, reaction times and false alarms from the RVIP, and
mental fatigue ratings. There were two measure each for state
anxiety (on arriving at the laboratory and immediately fol-
lowing the CDB) and salivary caﬀeine (immediately prior to
drink consumption and immediately after the CDB).
To test for chance baseline diﬀerences which may have
skewed change-from-baseline scores, prior to the primary sta-
tistical analysis, all pre-dose baseline measures were subjected
to one-way repeated measures ANOVAs. In the case of sali-
vary caﬀeine, baseline levels were also examined to assess
compliance to caﬀeine abstinence instructions. Additionally
to ascertain any interactions with treatment order, initial
three-way (treatment order treatment time) ANOVAs
were conducted incorporating the six treatment orders from
the Latin square.
The primary analyses (where there was no interaction
with, or main eﬀect of treatment order) involved two-way
(treatment time) repeated measures ANOVAs on ‘change-
from-baseline’ data from each CDB measure. At each
post-treatment time point, the score from the ﬂavanol-poor
control was compared to that for each of the two active treat-
ments using planned comparisons, utilising t-tests with
MSError from an omnibus ANOVA as an error term
(Keppel, 1991). All testing was two-tailed, comparisons
were strictly planned prior to the study, were restricted to
the number of conditions minus one at each time point, and
only probabilities associated with these pre-planned compar-
isons were calculated.
All analyses were performed using SPSS v15 for Windows.
Results
Baseline scores
There were no statistically signiﬁcant baseline diﬀerences for
any measure.
Treatment order
For state anxiety there was a signiﬁcant main eﬀect of treat-
ment order [F(5.24) ¼ 2.667, p¼ 0.047]. There were no other
main eﬀects nor interactions with treatment order, therefore
results of treatment t time ANOVAs are reported.
Table 1. Nutritional content of the three study beverages
low CF
control drink
‘520 CF’
drink
‘994 CF’
drink
Total cocoa flavanols,
mg, comprising:
46 520 994
Epicatechin 4 94 184
Catechin 8 35 62
Dimers 10 96 182
Trimers-decamers 24 295 566
Calories 216 217 218
Total fat, g 2.6 2.6 2.6
Sat. fat, g 1.4 1.4 1.4
Cholesterol, mg 9.8 9.5 9.2
Total carbohydrate, g 30.8 31.2 31.6
Dietary fibre, g 7.4 6.5 5.6
Sugars, g 17.2 17.4 17.6
Protein, g 17 17 17
Caffeine, mg 46.4 43.5 40.6
Theobromine, mg 400.2 429.2 458.2
Sodium, mg 450 415.2 380.4
Potassium, mg 1194.8 1087.5 980.2
Calcium, mg 451.2 454.7 458.2
Iron, mg 8.6 6.6 4.6
Phosphorus, mg 495.6 508.5 521.4
Magnesium, mg 141 149.4 157.8
Zinc, mg 3 2.9 2.8
Copper, mg 0.8 0.7 0.6
Manganese, mg 1 1.1 1.2
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Salivary caffeine levels
Salivary analysis conﬁrmed adherence to caﬀeine abstinence
instructions with mean baseline caﬀeine values of 0.35mg/ml
(levels just below 1 mg/ml have been reported for overnight
caﬀeine abstinence (Evans and Griﬃths, 1999). There was a
signiﬁcant main eﬀect of time [F(1.46)¼ 24.533, p< 0.001]
with higher caﬀeine levels at the second, ﬁnal reading than
pre-treatment, conﬁrming that the three drinks were matched
for caﬀeine content (see Table 1). There was no signiﬁcant
main eﬀect of treatment, nor any treatment time
interaction.
State anxiety
There were no signiﬁcant eﬀects on the Spielberger state anx-
iety questionnaire (F< 1 in all cases), but see ‘Treatment
order’ above.
Cognitive demand battery
Mean pre-dose baseline, and change from baseline scores for
each intervention are presented in Table 2, along with
F-values and probabilities associated with treatment eﬀects.
Change from baseline scores for each variable are also plotted
in Figure 2.
Serial Three subtractions: Compared with the control
drink, the number of correct serial threes was signiﬁcantly
increased following consumption of drinks containing both
the 520 and 994mg CF (Figure 2a). There were a higher
number of correct responses following the consumption of
520mg CF at all time points of the battery (10min
[t(290)¼ 2.91, p¼ 0.004], 20min [t(290)¼ 3.48, p¼ 0.0006],
30min [t(290)¼ 3.07, p¼ 0.002], 40min [t(290)¼ 4.51,
p< 0.00001], 50min [t(290)¼ 3.62, p¼ 0.0004], and 60min
[t(290)¼ 2.56, p¼ 0.01]). Following consumption of 994mg
CF, the number of correct responses was signiﬁcantly incre-
ased at 10min [t(290)¼ 2.26, p¼ 0.02], 20min [t(290)¼ 2.80,
p¼ 0.005], 30min [t(290)¼ 2.26, p¼ 0.02], and 40min
[t(290)¼ 3.83, p¼ 0.0002]. There were a single statistically sig-
niﬁcant eﬀects of drink condition on number of Serial Three
errors (Figure 2b), with fewer errors at 20min following
994mg CF drink compared with the control [t (290)¼ 1.98,
p¼ 0.048]
Serial Seven subtractions: There were no statistically signif-
icant eﬀects associated with either active drink on the number
of Serial Sevens completed (see Figure 2c). Consumption of the
994mg CF drink was associated with signiﬁcantly more errors
at 30min [t(290)¼ 2.31, p¼ 0.02] and 40min [t(290) ¼ 5.19,
p< 0.00001], see Figure 2d.
RVIP: There were no signiﬁcant treatment eﬀects on RVIP
accuracy (see Figure 2e). Following the 994mg CF drink,
State anxiety
Practice CDB
Baseline CDB
Saliva sample
TREATMENT
90 min
CDB
State anxiety
Serial threes
Serial threes
Serial sevens
Serial sevens
RVIP
RVIP
Mental fatigue
Mental fatigue
(2 min)
(2 min)
(2 min)
(2 min)
(5 min)
(5 min)
(1 min)
(1 min)
rating
Serial threes Serial sevens RVIP Mental fatigue
(2 min) (2 min) (5 min) (1 min)rating
rating
Minutes
of
battery
1–2
11–12
21–22
31–32
41–42
51–52
3–4
13–4
23–2
33–34
43–44
53–54
5–9 10
20
30
40
50
60
15–19
25–29
35–39
45–49
55–59
Figure 1. Structure of study days. An initial 10-min Cognitive Demand Battery (CDB) was followed by the day’s baseline CDB. A saliva sample was taken
for determination of caffeine prior to the day’s treatment. 90 min was allowed for absorption of CF followed by six cycles of the 10-min CDB (with
minutes of battery shown in relation to tasks). State anxiety was assessed at the beginning and end of the procedure.
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participants were signiﬁcantly faster on the RVIP task at 30min
[t(260)¼ 2.27, p¼ 0.02] and 40min [t(260)¼ 2.55, p¼ 0.01], see
Figure 2f. There were no signiﬁcant treatment eﬀects on the
number of false alarms during this task (see Figure 2g).
Mental fatigue VAS: Following the 520mg CF drink, self-
rated mental fatigue was signiﬁcantly improved at all but the
30min time point (10mins [t(280)¼ 2.85, p¼.0047], 20min
[t(280)¼ 2.76, p¼ 0.006], 40min [t(280)¼ 2.89, p¼.004],
50min [t(280)¼ 2.83, p¼ 0.005], and 60min [t(280)¼ 3.48,
p¼ 0.0006]), see Figure 2h.
Discussion
The results of the current study demonstrate, for the ﬁrst
time, that the acute consumption of CF can improve perfor-
mance and reduce ‘mental fatigue’ during highly eﬀortful
cognitive processing in healthy young participants.
Compared with the nutrient-matched, low ﬂavanol control
drink, improvements to cognition and mood were evident
following consumption of both 520mg CF and 994mg CF.
Of these, the 520mg CF drink appeared to be more beneﬁcial.
Both CF-rich drinks positively inﬂuenced the same perfor-
mance measures, but there was also some ‘cost’ to perfor-
mance following the 994mg CF drink. Moreover the
beneﬁts associated with the 520mg CF drink were apparent
at a greater number of time points and included reduced
mental fatigue ratings. The test drinks were matched for
other nutritional and alkaloid content, thus we can be rea-
sonably conﬁdent that these eﬀects are attributable to CF
rather than other components in the product.
Consumption of 520mg CF reliably improved Serial
Threes performance. These improvements were demonstrated
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at each post-dose completion of the battery with the most
striking improvement during the fourth CDB cycle (130min
post-CF). Improved Serial Threes performance was also
observed for the 994mg CF intervention. However, this
eﬀect was less striking and apparent only for the ﬁrst four
cycles of the battery (again with the most signiﬁcant improve-
ment during the fourth cycle). Consumption of 994mg CF led
to faster RVIP during the third and fourth completion, an
eﬀect not seen following the 520mg CF. The only negative
eﬀect was also associated with 994mg CF, with more Serial
Sevens errors during the third and fourth cycle.
The diﬀerential eﬀects to Serial Threes and Serial Sevens in
the current study has been observed previously. Utilising the
same Cognitive Demand battery as here, (Reay et al., 2005)
found signiﬁcant improvements to Serial Sevens but no inter-
pretable eﬀect on Serial Threes following 200mg Panax gin-
seng. Conversely, in a follow-up study, Reay et al. (2006)
found the opposite pattern. Kennedy and Scholey (2004)
also found improvements to Serial Sevens following con-
sumption of 68 g glucose plus 46mg caﬀeine with no eﬀects
on Serial Threes. These data suggests that the two tasks may
draw on diﬀerent neurocognitive substrates. Both tasks have
attentional components, but Serial Threes may be more lim-
ited by psychomotor performance, whereas the Serial
Sevens task relies more heavily on working memory and exec-
utive function. These results again demonstrate the utility of
the battery in capturing acute eﬀects of nutritional
interventions.
Turning to the subjective outcomes, following the con-
sumption of 520mg CF, there was an attenuation of the char-
acteristic increase in ‘mental fatigue’ seen with successive
completions of this battery. Mental fatigue ratings following
consumption of 520mg CF were signiﬁcantly lower than pla-
cebo during all but the third cycle of the of the battery. There
were no eﬀects on this measure following consumption of
994mg CF. ‘State anxiety’ was unaﬀected by any treatment.
In the current study, the greatest number and most robust
mood and cognition eﬀects were seen at the during the fourth
CDB cycle, i.e.130min post-CF ingestion. This time point
more or less coincides with the 2 h post-CF peak in CBF
(Francis et al., 2006) and plasma epicatechin levels (Rein
et al., 2000) reported in previous studies. Our intention was
to examine any relationship between plasma ﬂavonoids and
neurocognitive function, unfortunately damage to samples
during shipping prevented this from happening.
Although analysis of blood ﬂavanols was not possible, it
may be that blood sampling inﬂuenced anxiety levels. Anxiety
appeared not to be inﬂuenced by the CDB or by CF, however
as this was the single measure which was signiﬁcantly aﬀected
by treatment order we cannot draw any conclusions about
anxiety from this study. It is also possible that anxiety may
have been inﬂuenced by the methylxanthines contained within
the CF drinks. Although these were well matched across
drinks (see Table 1), there were small diﬀerences.
Furthermore we cannot rule out the possibility of caﬀeine,
theobromine or indeed other components of the drinks such
as magnesium (Grassi et al., 2005a) interacting diﬀerentially
with CF to produce the eﬀects seen here.
The eﬀects of lower levels of CF appear to merit further
exploration and, if possible, the lowest psychoactive dose
should be established. Of relevance here is a recent ﬁnding
of impairment to performance following consumption of very
low doses of caﬀeine (Haskell et al., 2008). However unlikely,
this raises the possibility that acute negative eﬀects may occur
in response to low levels of CF, this would serve to exaggerate
the eﬀects of the two higher CF preparations in the current
study. The possibility could be addressed with a partial rep-
lication of the current study with the inclusion of an addi-
tional, ﬂavanol-free arm.
The eﬀects of consuming 520mg CF on Serial Threes and
‘mental fatigue’ ratings were apparent during the ﬁrst cycle of
the CDB. This raises the possibility that cognitive beneﬁts
may have been observed if the CBD had commenced earlier
than 90min post-drink. The eﬀects seen 40min into the bat-
tery may also represent an optimal interaction between ﬂava-
nol levels and reduced resources due to the demanding and
fatiguing nature of the tasks. It is also possible that eﬀects
were most pronounced at this point due to participants reach-
ing a peak in stress levels. If so we might attribute adapto-
genic (or resistance-increasing) properties to CF. This could
be further explored by monitoring performance during psy-
chological stress following CF ingestion. Although adapto-
genic plants have been shown to have acute eﬀects
(Panossian and Wagner, 2005), by deﬁnition – i.e. producing
adaptive adjustments – they are traditionally thought of as
building resistance to stressful events through chronic rather
than acute administration. It would therefore be of great
interest to explore the role of CF as adaptogens by studying
their chronic eﬀect and comparing to those elicited acutely as
in the current study. Certainly there is epidemiological evi-
dence to suggest that long-term ﬂavanol intake has neurocog-
nitive beneﬁts including neuroprotection (for reviews see
Commenges et al., 2000; Letenneur et al., 2007; Patel et al.,
2008; Spencer, 2008). On the other hand, seemingly compel-
ling epidemiological data are often not translated into posi-
tive ﬁndings in clinical trials. Nevertheless future studies
might usefully collect data regarding include habitual con-
sumption of methylxanthine, CF and other drink components
which may have interacted with ﬂuctuations in acute levels to
inﬂuence aspects of cognitive performance.
The exact mechanisms by which CF may beneﬁt cognitive
processing remain unknown. There has been a great deal of
focus on the anti-oxidant properties of CF. However this
notion has recently been challenged (for reviews see Frei,
2004; Halliwell, 2008). Firstly CF undergo extensive biotrans-
formation following ingestion rendering molecules with
greatly reduced anti-oxidant capacity, and the absorbed frag-
ments of CF do not possess the anti-oxidant properties
observed in the whole molecule. Additionally it appears that
there may have been over-interpretation of CF anti-oxidant
capacity ex vivo. Thus it seems that the anti-oxidant proper-
ties of CF may have been overstated and this role remains to
be substantiated in physiological systems using realistic levels
of orally administered CF.
Previous studies have shown that the acute consumption of
200–500mg of CF is able to increase blood vessel dilation
(Heiss et al., 2003, 2005, 2007; Engler et al., 2004). We have
previously hypothesized that the delivery of metabolic sub-
strates contributes to enhanced performance of cognitively dema-
nding tasks (Scholey, 2001; Scholey et al., 2001, 2006, 2008;
8 Journal of Psychopharmacology 0(00)
XML Template (2009) [17.9.2009–6:11pm] [1–10]
K:/JOP/JOP 106923.3d (JOP) [INVALID Stage]
Scholey and Kennedy, 2004). If true then it seems plausible
that such eﬀects may underlie the cognitive beneﬁts observed
here. Indeed the fact that peak behavioural eﬀects were
observed at around two hours post-consumption is consistent
with peak plasma epicatechin levels (Rein et al., 2000), cerebral
blood ﬂow (Francis et al., 2006) and dose-dependent increases
in ﬂow-mediated dilatation (FMD) peaking at the same time
point (Schroeter et al., 2006). Similar observations have been
made in diabetic patients (Balzer et al., 2008), healthy over-
weight individuals (Faridi et al., 2008) and healthy smokers
(Hermann et al., 2006). These results support previous ﬁndings
which have shown that natural products which increase cere-
bral blood ﬂow and/ormetabolic activity are particularly eﬀec-
tive in improving cognitive processing during prolonged
mental eﬀort. On the other hand it should also be noted that
a recent study found no acute eﬀect of 450mg CF on cerebral
blood ﬂow (CBF) in healthy elderly individuals (Sorond et al.,
2008). The study reported increased mean ﬂow velocity (MFV)
in the middle cerebral artery measured by Doppler ultrasound
after one and two weeks CF supplementation. The eﬀects
reached signiﬁcance 8 h following CF treatment on days 7
and 14. However there were no signiﬁcant eﬀects on this
measure on day 1, indeed there was a slight (non-signiﬁcant)
fall in MFV 2–4 h post CF consumption. The diﬀerence in
these ﬁndings and those reporting acute increases to measures
of vaso-activity most likely represent diﬀerences in speciﬁc
measures used.
In conclusion we believe that this is the ﬁrst report of acute
cognitive beneﬁts to cognitive function associated with CF
consumption in healthy volunteers. These ﬁndings suggest
that the consumption of 520mg CF (and to a lesser extent
994mg CF) may be beneﬁcial to performance and mood
during highly eﬀortful cognitive processing. These eﬀects
merit further exploration in other populations, over longer
time scales, at diﬀerent doses, while co-monitoring relevant
biomarkers (including neuroimaging) and in other cognitive
domains.
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